CD38+ NK/T cells define responsiveness to Bi-specific T cell engagers in high-risk MAD5+RPILD: a real-world study and immune surveillance analysis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #943; Pres time: Nov 8, 2026; 04:15 PM - 04:30 PM; Location: W304 A-H; In Person; "Blinatumomab is well-tolerated and shows potential in improving 1-year survival and lung radiology for high-risk MDA5+ RPILD. Sustained CD38hi NK/T cell expansion with high cytotoxic and dysfunctional gene expression serves as a key indicator of treatment failure and poor prognosis, guiding future personalized therapeutic stratifications."
Bispecific • Clinical • IO biomarker • Real-world • Real-world evidence • Dermatomyositis • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Myositis • Pneumonia • Pulmonary Disease • Respiratory Diseases • CD27 • CD8 • GZMB • GZMH • IFIH1 • IL7R • NKG7 • PRF1
|
|
Runci Wang1; Yakai Fu1; Yiyangzi Ma1; Can Xia1; Zhiwei Chen2; Jie Chen1; Liyang Gu1; Wei Fan1; Xiaodong Wang1; Qiong Fu3; SHUANG YE1
|